Felycin-CA1

(sirolimus delayed-release tablets)

Indicated for the management of ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM). Conditionally approved by FDA pending a full demonstration of effectiveness under application 141-604.

FE0700 - Felycin-CA1 tablets 0.4mg, 12 tablets/ box

FE0711 - Felycin-CA1 tablets 1.2mg, 12 tablets/ box

FE0712 - Felycin-CA1 tablets 2.4mg, 12 tablets/ box

For vet clinics interested in this product, please contact our team here for pricing details and further information. Thank you.